telavancin

01/01/2009 - "In randomized, double-blind trials, intravenous telavancin 10 mg/kg once daily (administered as a 1-hour infusion) was effective in the treatment of adult patients with cSSSIs, including those with infections caused by MRSA, as shown by clinical cure rates in clinically evaluable, all-treated and microbiologically evaluable populations at the test-of-cure (TOC) visit. "
01/01/2015 - "Telavancin has been studied in several in vitro biofilm models and has demonstrated efficacy against staphylococcal and enterococcal-associated biofilm infections, including those formed by methicillin-resistant Staphylococcus aureus. "
06/01/2012 - "Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections."
07/01/2008 - "These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms."
06/01/2005 - "aureus infection at baseline (n = 102), 80% of the telavancin group were cured and 77% of the standard therapy group were cured. "

07/01/2007 - "Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus."
08/01/2005 - "Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus."
12/01/2010 - "Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin."
06/01/2010 - "Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin."
07/01/2017 - "Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports."

07/01/2016 - "We also searched for evidence of the efficacy of telavancin as demonstrated in clinical trials, safety and tolerability data and have compiled a summary of clinical trials on telavancin in pneumonia. "
12/16/2020 - "Telavancin is a potential new therapeutic alternative, specifically in monomicrobial MRSA pneumonia. "
11/01/2016 - "Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)."
07/01/2016 - "Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia."
03/01/2015 - "In Europe, telavancin is a useful alternative for patients with difficult-to-treat, hospital-acquired MRSA pneumonia when there are very few alternatives. "

01/01/2021 - "Data analysed from SSTIs, HAP and bacteremia studies on telavancin showed insignificant high clinical response in microbiologically evaluable patients infected with methicillin resistant Staphylococcus aureus (MRSA) (OR: 1.57, CI: 0.94-2.62, p: 0.08) and in the eradication of MRSA (OR: 1.39, CI: 0.99-1.96, P:0.06). "
09/01/2017 - "Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies."
06/01/2015 - "Further randomized, controlled trials are necessary to define the optimal role of telavancin in the treatment of MRSA bacteremia and IE."
06/01/2017 - "The efficacy and safety of telavancin is under evaluation for the treatment of subjects with complicated Staphylococcus aureus bacteremia and S. "
03/01/2017 - "aureus bacteremia [Telavancin for Treatment of Uncomplicated S. "

12/01/2012 - "In phase 3 studies of the efficacy of telavancin for the treatment of hospital-acquired pneumonia, 704 Gram-positive and 627 Gram-negative aerobic bacterial pathogens were obtained at baseline from 1503 patients. "
12/16/2020 - "However, studies are needed to confirm the benefits of telavancin in treating MRSA nosocomial pneumonia."
10/01/2018 - "Retrospective, descriptive analysis of data from the safety population from the Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials. "
03/01/2017 - "Phase III clinical trials have been carried out for evaluating telavancin's safety and efficacy in nosocomial pneumonia [Assessment of Telavancin for Treatment of Hospital acquired Pneumonia 1 and 2 (ATTAIN 1 and ATTAIN 2)]. "
12/01/2014 - "Telavancin now has approval for treatment of hospital-acquired pneumonia, and recent phase 2 trial data showed similar cure rates in S. "